Table 1 Demographics for patients whose tumors were subjected to whole exome sequencing (n = 43)
From: Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape
MS ID** | Sex | Age*** | Mitotane | Systemic therapy prior to metastatectomy | DOD | Hormonally active |
|---|---|---|---|---|---|---|
13 | F | 20′s | Yes | Mitotane MAVE Taxol Cisplatin | Alive | Yes, Cushing syndrome |
43 | F | 20′s | Yes |  | Dead | Yes, Cushing syndrome |
9 | F | 20′s | Yes |  | Alive | Unknown |
17 | F | 20′s | Yes |  | Dead | No |
4 | F | 20′s | No |  | Dead | Yes, Cushing syndrome |
30 | F | 20′s | Yes | Mitotane | Alive | No |
32 | F | 30′s | Yes | T-MAVE | Dead | No |
11 | F | 30′s | Yes | EDP | Alive | No |
38 | F | 30′s | Yes |  | Alive | Yes, Cushing syndrome |
12 | F | 30′s | Yes | T-MAVE | Alive | No |
31 | F | 40′s | Yes | T-MAVE | Dead | No |
36 | F | 40′s | Yes |  | Dead | Yes, aldosterone |
26 | F | 40′s | Yes | MAVE | Dead |  |
42 | F | 40′s | Yes |  | Dead | Yes, testosterone |
3 | F | 40′s | Yes | T-MAVE Gemzar/Cisplatin | Alive | Yes, based on symptoms |
34 | F | 40′s | No |  | Dead | Yes, Cushing syndrome |
40 | F | 40′s | Yes | Mitotane × 2 months | Dead | No |
1 | F | 40′s | Yes | EDP | Dead | Yes, based on symptoms |
27 | F | 40′s | No | Cisplatin prior to primary resection; cisplat in & axitinib prior to metastatic resection | Dead | Yes, Cushing syndrome |
23 | F | 50′s | Yes |  | Dead | Yes, likely Cushing syndrome |
2 | F | 50′s | Yes | IMC-A12, mitotane | Dead | Yes, Cushing syndrome |
16 | F | 50′s | Yes | T-MAVE | Dead | Yes, Cushing syndrome |
44 | F | 50′s | Yes | EDP/M | Alive | Yes, Cushing syndrome based on symptoms |
15 | F | 50′s | Yes | EDP/M | Dead | No, palpitations, HTN, sweating |
25 | F | 50′s | Yes | Mitotane | Alive | No |
21 | F | 50′s | Yes | OSI-906, EDP/M, Streptozocin | Dead | No |
29 | F | 50′s | Yes |  | Dead | Yes, based on symptoms |
24 | F | 50′s | No |  | Dead | No, h/o HTN |
5 | F | 50′s | Yes | EDP/M, Streptozocin | Dead | No |
7 | F | 60′s | Yes | T-MAVE | Alive | No |
39 | M | 30′s | No | PSC-Velban | Alive | No |
35 | M | 30′s | Yes | MAVE | Dead | No |
19 | M | 30′s | Yes | Mitotane | Dead | No |
33 | M | 30′s | Yes | EDP/M | Dead | No, h/o hypokalemia |
10 | M | 40′s | Yes | Mitotane, streptozocin, cisplatin | Dead | Yes, Cushing syndrome |
8 | M | 50′s | No |  | Dead | No |
37 | M | 50′s | Yes | Mitotane | Dead | Yes, Cushing syndrome |
6 | M | 50′s | No |  | Dead | No |
28 | M | 50′s | No | Cisplatin, mithramycin | Dead | Yes, estradiol |
22 | M | 50′s | Yes | EDP/M | Dead | No |
14 | M | 50′s | Yes | EDP/M | Dead | No |
41 | M | 60′s | Yes | MAVE, Etoposide + Carboplatin | Dead | No |
20 | M | 70′s | No |  | Dead | No |